

Edward V Prochownik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2234890/publications.pdf>

Version: 2024-02-01

106
papers

7,144
citations

53751

45
h-index

60583

81
g-index

112
all docs

112
docs citations

112
times ranked

8711
citing authors

#	ARTICLE	IF	CITATIONS
1	MYC oncogenes and human neoplastic disease. <i>Oncogene</i> , 1999, 18, 3004-3016.	2.6	1,049
2	Low molecular weight inhibitors of Myc-Max interaction and function. <i>Oncogene</i> , 2003, 22, 6151-6159.	2.6	382
3	Mutation of the MXI1 gene in prostate cancer. <i>Nature Genetics</i> , 1995, 9, 249-255.	9.4	208
4	Regulation of reactive oxygen species, DNA damage and c-Myc function by peroxiredoxin 1. <i>Oncogene</i> , 2005, 24, 8038-8050.	2.6	205
5	Differential Interactions of Id Proteins with Basic-Helix-Loop-Helix Transcription Factors. <i>Journal of Biological Chemistry</i> , 1997, 272, 19785-19793.	1.6	200
6	Multiple Independent Binding Sites for Small-Molecule Inhibitors on the Oncoprotein c-Myc. <i>Journal of the American Chemical Society</i> , 2009, 131, 7390-7401.	6.6	193
7	Improved low molecular weight Myc-Max inhibitors. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2399-2408.	1.9	177
8	Structural Rationale for the Coupled Binding and Unfolding of the c-Myc Oncoprotein by Small Molecules. <i>Chemistry and Biology</i> , 2008, 15, 1149-1155.	6.2	151
9	The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues. <i>Frontiers in Endocrinology</i> , 2018, 9, 129.	1.5	142
10	Therapeutic Targeting of Myc. <i>Genes and Cancer</i> , 2010, 1, 650-659.	0.6	135
11	Molecular Heterogeneity of Inherited Antithrombin III Deficiency. <i>New England Journal of Medicine</i> , 1983, 308, 1549-1552.	13.9	128
12	C-myc overexpression and p53 loss cooperate to promote genomic instability. <i>Oncogene</i> , 1999, 18, 1177-1184.	2.6	128
13	Small-molecule inhibitors of the Myc oncoprotein. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2015, 1849, 525-543.	0.9	127
14	Pag, a Putative Tumor Suppressor, Interacts with the Myc Box II Domain of c-Myc and Selectively Alters Its Biological Function and Target Gene Expression. <i>Journal of Biological Chemistry</i> , 2002, 277, 43175-43184.	1.6	117
15	c-Myc: Linking Transformation and Genomic Instability. <i>Current Molecular Medicine</i> , 2008, 8, 446-458.	0.6	110
16	Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. <i>Oncogene</i> , 1999, 18, 3564-3573.	2.6	109
17	Mitochondrial Structure, Function and Dynamics Are Temporally Controlled by c-Myc. <i>PLoS ONE</i> , 2012, 7, e37699.	1.1	108
18	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2011, 208, 1595-1603.	4.2	104

#	ARTICLE	IF	CITATIONS
19	Efficacy, pharmacokinetics, tissue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidene]-2-thioxothiazolidin-4-one, in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 615-625.	1.1	101
20	In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 715-727.	1.3	96
21	Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway. <i>Oncogene</i> , 2005, 24, 7524-7541.	2.6	95
22	c-Myc Programs Fatty Acid Metabolism and Dictates Acetyl-CoA Abundance and Fate. <i>Journal of Biological Chemistry</i> , 2014, 289, 25382-25392.	1.6	93
23	Lysine desuccinylase SIRT5 binds to cardiolipin and regulates the electron transport chain. <i>Journal of Biological Chemistry</i> , 2017, 292, 10239-10249.	1.6	87
24	c-Myc as a therapeutic target in cancer. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 289-302.	1.1	86
25	Discovery of Novel Myc-Max Heterodimer Disruptors with a Three-Dimensional Pharmacophore Model. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1247-1250.	2.9	81
26	The High-Mobility Group A1 Gene Up-Regulates Cyclooxygenase 2 Expression in Uterine Tumorigenesis. <i>Cancer Research</i> , 2007, 67, 3998-4004.	0.4	76
27	Perturbation of the c-Myc-Max Protein-Protein Interaction via Synthetic α -Helix Mimetics. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3002-3024.	2.9	76
28	Targeting of the MYCN Protein with Small Molecule c-MYC Inhibitors. <i>PLoS ONE</i> , 2014, 9, e97285.	1.1	74
29	Regulation of Reactive Oxygen Species Homeostasis by Peroxiredoxins and c-Myc. <i>Journal of Biological Chemistry</i> , 2009, 284, 6520-6529.	1.6	73
30	Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 1998, 22, 295-304.	1.5	72
31	Endothelial Progenitors Exist within the Kidney and Lung Mesenchyme. <i>PLoS ONE</i> , 2013, 8, e65993.	1.1	69
32	Dynamic Regulation of ME1 Phosphorylation and Acetylation Affects Lipid Metabolism and Colorectal Tumorigenesis. <i>Molecular Cell</i> , 2020, 77, 138-149.e5.	4.5	63
33	The Ever Expanding Role for c-Myc in Promoting Genomic Instability. <i>Cell Cycle</i> , 2007, 6, 1024-1029.	1.3	62
34	miR-148a inhibits colitis and colitis-associated tumorigenesis in mice. <i>Cell Death and Differentiation</i> , 2017, 24, 2199-2209.	5.0	62
35	C-Myc-Independent Restoration of Multiple Phenotypes by Two C-Myc Target Genes with Overlapping Functions. <i>Cancer Research</i> , 2005, 65, 2097-2107.	0.4	61
36	Diagnostic and prognostic implications of ribosomal protein transcript expression patterns in human cancers. <i>BMC Cancer</i> , 2018, 18, 275.	1.1	61

#	ARTICLE	IF	CITATIONS
37	The IKK β -USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis. <i>Hepatology</i> , 2021, 73, 160-174.	3.6	61
38	Pharmacophore identification of c-Myc inhibitor 10074-G5. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 370-374.	1.0	59
39	Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma. <i>Journal of Biological Chemistry</i> , 2017, 292, 10068-10086.	1.6	57
40	Genetic dissection of c-myc apoptotic pathways. <i>Oncogene</i> , 2000, 19, 3200-3212.	2.6	56
41	The Metabolic Fates of Pyruvate in Normal and Neoplastic Cells. <i>Cells</i> , 2021, 10, 762.	1.8	56
42	Relationship between an enhancer element in the human antithrombin III gene and an immunoglobulin light-chain gene enhancer. <i>Nature</i> , 1985, 316, 845-848.	13.7	55
43	Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9 both contribute to disease severity in ACAD9 deficiency. <i>Human Molecular Genetics</i> , 2015, 24, 3238-3247.	1.4	53
44	Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1286-1294.	1.9	52
45	MicroRNA-148a deficiency promotes hepatic lipid metabolism and hepatocarcinogenesis in mice. <i>Cell Death and Disease</i> , 2017, 8, e2916-e2916.	2.7	49
46	Coordinated Activities of Multiple Myc-dependent and Myc-independent Biosynthetic Pathways in Hepatoblastoma. <i>Journal of Biological Chemistry</i> , 2016, 291, 26241-26251.	1.6	48
47	The Negative c-Myc Target Onzin Affects Proliferation and Apoptosis via Its Obligate Interaction with Phospholipid Scramblase I. <i>Molecular and Cellular Biology</i> , 2006, 26, 3401-3413.	1.1	47
48	Permanently Blocked Stem Cells Derived From Breast Cancer Cell Lines. <i>Stem Cells</i> , 2010, 28, 1008-1018.	1.4	47
49	c-Myc Is Required for the ChREBP-Dependent Activation of Glucose-Responsive Genes. <i>Molecular Endocrinology</i> , 2010, 24, 1274-1286.	3.7	46
50	Disruption of Myc-Max Heterodimerization with Improved Cell-Penetrating Analogs of the Small Molecule 10074-G5. <i>Oncotarget</i> , 2013, 4, 936-949.	0.8	45
51	Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids. <i>Oncotarget</i> , 2015, 6, 32380-32395.	0.8	45
52	The MAP3K13-TRIM25-FBXW7 axis affects c-Myc protein stability and tumor development. <i>Cell Death and Differentiation</i> , 2020, 27, 420-433.	5.0	44
53	Assignment of the Human MAD and MXI1 Genes to Chromosomes 2p12-p13 and 10q24-q25. <i>Genomics</i> , 1994, 23, 282-285.	1.3	42
54	Distinct Roles for MAX Protein Isoforms in Proliferation and Apoptosis. <i>Journal of Biological Chemistry</i> , 1997, 272, 17416-17424.	1.6	39

#	ARTICLE	IF	CITATIONS
55	Myc and ChREBP transcription factors cooperatively regulate normal and neoplastic hepatocyte proliferation in mice. <i>Journal of Biological Chemistry</i> , 2018, 293, 14740-14757.	1.6	39
56	β-Catenin mutations as determinants of hepatoblastoma phenotypes in mice. <i>Journal of Biological Chemistry</i> , 2019, 294, 17524-17542.	1.6	39
57	Abnormal lipid processing but normal long-term repopulation potential of <i>c-myc</i> hepatocytes. <i>Oncotarget</i> , 2016, 7, 30379-30395.	0.8	39
58	Inhibition of reverse transcriptases of primate type C viruses by 7S immunoglobulin from patients with leukaemia. <i>Nature</i> , 1976, 260, 64-67.	13.7	37
59	Amplification of Glyceronephosphate O-Acyltransferase and Recruitment of USP30 Stabilize DRP1 to Promote Hepatocarcinogenesis. <i>Cancer Research</i> , 2018, 78, 5808-5819.	0.4	37
60	Discovery of Methyl 4-(7-nitrobenzo[1,2,5]oxadiazol-4-yl)-1,1-biphenyl-3-carboxylate, an Improved Small-Molecule Inhibitor of c-Myc Max Dimerization. <i>ChemMedChem</i> , 2014, 9, 2274-2285.	1.6	35
61	Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion. <i>Oncotarget</i> , 2015, 6, 15857-15870.	0.8	35
62	Embryonal rhabdomyosarcoma of the ampulla of Vater with long-term survival following pancreaticoduodenectomy. <i>Journal of Pediatric Surgery</i> , 1990, 25, 1256-1258.	0.8	31
63	Novel Regulation of the Helix-Loop-Helix Protein Id1 by S5a, a Subunit of the 26 S Proteasome. <i>Journal of Biological Chemistry</i> , 1997, 272, 19140-19151.	1.6	31
64	Genetic Dissociation of Glycolysis and the TCA Cycle Affects Neither Normal nor Neoplastic Proliferation. <i>Cancer Research</i> , 2017, 77, 5795-5807.	0.4	31
65	Dynamic in vivo interactions among Myc network members. <i>Oncogene</i> , 2001, 20, 4650-4664.	2.6	30
66	Ribosomopathy-like properties of murine and human cancers. <i>PLoS ONE</i> , 2017, 12, e0182705.	1.1	29
67	Myc Target in Myeloid Cells-1, a Novel c-Myc Target, Recapitulates Multiple c-Myc Phenotypes. <i>Journal of Biological Chemistry</i> , 2002, 277, 19998-20010.	1.6	28
68	In Vivo Evolution of Tumor-Derived Endothelial Cells. <i>PLoS ONE</i> , 2012, 7, e37138.	1.1	28
69	Breast Cancer Stem Cell-Like Cells Are More Sensitive to Ionizing Radiation than Non-Stem Cells: Role of ATM. <i>PLoS ONE</i> , 2012, 7, e50423.	1.1	28
70	P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis. <i>Hepatology</i> , 2023, 77, 1499-1511.	3.6	28
71	Small-molecule inhibitors of dimeric transcription factors: Antagonism of protein-protein and protein-DNA interactions. <i>MedChemComm</i> , 2012, 3, 541.	3.5	27
72	c-Myc and AMPK Control Cellular Energy Levels by Cooperatively Regulating Mitochondrial Structure and Function. <i>PLoS ONE</i> , 2015, 10, e0134049.	1.1	27

#	ARTICLE	IF	CITATIONS
73	Mmp1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc. <i>Oncogene</i> , 1998, 16, 1149-1159.	2.6	26
74	Deregulation of common genes by c-Myc and its direct target, MT-MC1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 18968-18973.	3.3	26
75	microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13. <i>Oncotarget</i> , 2016, 7, 16409-16419.	0.8	25
76	Establishment of an apoptosis-resistant and growth-controllable cell line by transfecting with inducible antisense c-Jun gene. , 1998, 58, 65-72.		24
77	Myc Is Required for Adaptive β^2 -Cell Replication in Young Mice but Is Not Sufficient in One-Year-Old Mice Fed With a High-Fat Diet. <i>Diabetes</i> , 2019, 68, 1934-1949.	0.3	23
78	Mmp-2, a novel RING finger protein that interacts with mad members of the Myc oncoprotein network. <i>Oncogene</i> , 1999, 18, 6621-6634.	2.6	22
79	Cyclin B1 Is a Critical Target of RhoB in the Cell Suicide Program Triggered by Farnesyl Transferase Inhibition. <i>Cancer Research</i> , 2004, 64, 8389-8396.	0.4	22
80	Metabolic and oncogenic adaptations to pyruvate dehydrogenase inactivation in fibroblasts. <i>Journal of Biological Chemistry</i> , 2019, 294, 5466-5486.	1.6	22
81	Inhibition of hepatocellular carcinoma by metabolic normalization. <i>PLoS ONE</i> , 2019, 14, e0218186.	1.1	20
82	The CCL6 chemokine is differentially regulated by c-Myc and L-Myc, and promotes tumorigenesis and metastasis. <i>Cancer Research</i> , 2003, 63, 2923-32.	0.4	20
83	c-Myc-mediated genomic instability proceeds via a megakaryocytic endomitosis pathway involving Gp1b β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3490-3495.	3.3	19
84	Point Mutations in c-Myc Uncouple Neoplastic Transformation from Multiple Other Phenotypes in Rat Fibroblasts. <i>PLoS ONE</i> , 2010, 5, e13717.	1.1	19
85	Ceramide-mediated gut dysbiosis enhances cholesterol esterification and promotes colorectal tumorigenesis in mice. <i>JCI Insight</i> , 2022, 7, .	2.3	18
86	Lack of transcriptional repression by max homodimers. <i>Oncogene</i> , 1998, 16, 2629-2637.	2.6	17
87	Mmp-2/Rnf-17 enhances c-Myc function and regulates some target genes in common with glucocorticoid hormones. <i>Oncogene</i> , 2001, 20, 2908-2917.	2.6	17
88	Endothelial-like cells derived directly from human tumor xenografts. <i>International Journal of Cancer</i> , 2010, 127, 2268-2278.	2.3	17
89	FBXL6 degrades phosphorylated p53 to promote tumor growth. <i>Cell Death and Differentiation</i> , 2021, 28, 2112-2125.	5.0	17
90	A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors. <i>Journal of Biological Methods</i> , 2015, 2, e18.	1.0	17

#	ARTICLE	IF	CITATIONS
91	USP19 exacerbates lipogenesis and colorectal carcinogenesis by stabilizing ME1. <i>Cell Reports</i> , 2021, 37, 110174.	2.9	15
92	Patient-Derived Mutant Forms of NFE2L2/NRF2 Drive Aggressive Murine Hepatoblastomas. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 199-228.	2.3	14
93	Phenotypic Screening Reveals Topoisomerase I as a Breast Cancer Stem Cell Therapeutic Target. <i>Oncotarget</i> , 2012, 3, 998-1010.	0.8	14
94	Coordinated Cross-Talk Between the Myc and Mlx Networks in Liver Regeneration and Neoplasia. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1785-1804.	2.3	12
95	Normal and Neoplastic Growth Suppression by the Extended Myc Network. <i>Cells</i> , 2022, 11, 747.	1.8	11
96	Widespread Genomic Instability Mediated by a Pathway Involving Glycoprotein Ib β and Aurora B Kinase. <i>Journal of Biological Chemistry</i> , 2010, 285, 13183-13192.	1.6	9
97	A Functional Hierarchy for c-Myc Target Genes? Lessons from MT-MC1. <i>Cell Cycle</i> , 2006, 5, 392-393.	1.3	8
98	Modularity of the Oncoprotein-like Properties of Platelet Glycoprotein Ib β . <i>Journal of Biological Chemistry</i> , 2009, 284, 1410-1418.	1.6	8
99	Expression patterns of small numbers of transcripts from functionally-related pathways predict survival in multiple cancers. <i>BMC Cancer</i> , 2019, 19, 686.	1.1	8
100	MicroRNA-Based Screens for Synthetic Lethal Interactions with c-Myc. <i>RNA & Disease (Houston, Tex)</i> , 2016, 3, .	1.0	7
101	Acquired deficiency of peroxisomal dicarboxylic acid catabolism is a metabolic vulnerability in hepatoblastoma. <i>Journal of Biological Chemistry</i> , 2021, 296, 100283.	1.6	6
102	Reconciling the Biological and Transcriptional Variability of Hepatoblastoma with Its Mutational Uniformity. <i>Cancers</i> , 2021, 13, 1996.	1.7	6
103	Sequential analysis of transcript expression patterns improves survival prediction in multiple cancers. <i>BMC Cancer</i> , 2020, 20, 297.	1.1	5
104	Commonly occurring loss and mutation of the MX11 gene in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 1998, 22, 295-304.	1.5	4
105	Rapid In Vitro Derivation of Endothelium Directly From Human Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e77675.	1.1	4
106	Liquid biopsies and the promise of what might(o) be. <i>Journal of Medical Artificial Intelligence</i> , 0, 2, 17-17.	1.1	1